CARA THERAPEUTICS INC. - COMMON STOCK

Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

21 Feb 2023 06:00:02 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine

08 Feb 2023 16:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023

17 Jan 2023 06:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 06:00:01 By Nasdaq GlobeNewswire

Cara Therapeutics Reports Third Quarter 2022 Financial Results

07 Nov 2022 15:01:01 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors

03 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at Upcoming Investor Conferences

02 Nov 2022 06:00:02 By Nasdaq GlobeNewswire

Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022

24 Oct 2022 06:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

28 Sep 2022 06:00:01 By Nasdaq GlobeNewswire

Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

12 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

08 Sep 2022 07:15:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

06 Sep 2022 06:00:01 By Nasdaq GlobeNewswire

Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022

24 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress

22 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022

19 Aug 2022 00:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Reports Second Quarter 2022 Financial Results

08 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

03 Aug 2022 06:00:01 By Nasdaq GlobeNewswire

Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022

01 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

30 Jun 2022 06:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at Upcoming Investor Conferences

17 May 2022 06:00:02 By Nasdaq GlobeNewswire